Translational research in neurology and neuroscience 2010: multiple sclerosis.
Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.
Stüve
Olaf
O
Neurology Section, VA North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA. olaf.stuve@utsouthwestern.edu
Kieseier
Bernd C
BC
Hemmer
Bernhard
B
Hartung
Hans-Peter
HP
Awad
Amer
A
Frohman
Elliot M
EM
Greenberg
Benjamin M
BM
Racke
Michael K
MK
Zamvil
Scott S
SS
Phillips
J Theodore
JT
Gold
Ralf
R
Chan
Andrew
A
Zettl
Uwe
U
Milo
Ron
R
Marder
Ellen
E
Khan
Omar
O
Eagar
Todd N
TN
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004195:Disease Models, Animal; D055808:Drug Discovery; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D000068717:Glatiramer Acetate; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000627:therapeutic use*; D057170:Translational Research, Biomedical
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D010455:Peptides; D000068717:Glatiramer Acetate